Kanerva A - Search Results

1

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: kanerva a. Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi: 10.1080/2162402X.2017.1412902. eCollection 2018. Oncoimmunology. 2018. PMID: 29721366 Free PMC article.

2

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

3

The flt-1 promoter for transcriptional targeting of teratocarcinoma.

Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT. Bauerschmitz GJ, et al. Among authors: kanerva a. Cancer Res. 2002 Mar 1;62(5):1271-4. Cancer Res. 2002. PMID: 11888889

4

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

5

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: kanerva a. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

6

CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.

Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT. Hakkarainen T, et al. Among authors: kanerva a. Clin Cancer Res. 2003 Feb;9(2):619-24. Clin Cancer Res. 2003. PMID: 12576427

7

Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT. Hemminki A, et al. Among authors: kanerva a. Cancer Res. 2003 Feb 15;63(4):847-53. Cancer Res. 2003. PMID: 12591736

8

A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.

Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT. Hemminki A, et al. Among authors: kanerva a. Mol Ther. 2003 Feb;7(2):163-73. doi: 10.1016/s1525-0016(02)00049-7. Mol Ther. 2003. PMID: 12597904 Free article.

9

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. Barker SD, et al. Among authors: kanerva a. J Gene Med. 2003 Apr;5(4):300-10. doi: 10.1002/jgm.341. J Gene Med. 2003. PMID: 12692864

10

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A. Kanerva A, et al. Mol Ther. 2003 Sep;8(3):449-58. doi: 10.1016/s1525-0016(03)00200-4. Mol Ther. 2003. PMID: 12946318 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters